Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20170045 | 0.79 | SMN1; SMN2 (0.43) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL5599103 | 0.72 | KMT2A (0.49) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL11134639 | 0.69 | SMN1; SMN2 (0.41) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL5599082 | 0.68 | SMN1; SMN2 (0.46) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL4253446 | 0.66 | SMN1; SMN2 (0.53) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL5489748 | 0.62 | SMN1; SMN2 (0.44) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL20936054 | 0.62 | SMN1; SMN2 (0.44) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL19102433 | 0.62 | SMN1; SMN2 (0.44) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL12499138 | 0.62 | SMN1; SMN2 (0.44) | SMN1; SMN2GLAKMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL10712476 | 0.58 | SMN1; SMN2 (0.41) | SMN1; SMN2GLAKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3323820-A1 | SUBSTITUTED 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |